Particle.news
Government ❯ Regulatory Agencies ❯ FDA
Mifepristone Public Health Compounding Regulations Mifepristone Review Over-the-Counter Drugs MDMA for PTSD Biologics License Application Public Health Regulations Clinical Trial Regulations Ranitidine Regulations Inspections Medication Safety Over-the-Counter Medications Accelerated Approval Tirzepatide Supply Breakthrough Therapy Designation Legislation Compliance Animal Welfare Policies Ethical Standards in Testing Animal Welfare Clinical Data Requirements Enforcement Actions Biotech Innovation Safety Concerns Clinical Study Regulations Safety Communications Market Withdrawal Risks Telemedicine Regulations Orphan Drug Designation Patient Safety Labeling Regulations Vaccine Licensing Vaccine Approval Import Regulations Public Health Initiatives Clinical Guidelines Complete Response Letters Generic Drugs Mifepristone Approval Public Communication New Drug Application MDMA MDMA Trials Alzheimer's Drug Approval Insulin Icodec MDMA Approval Psychedelic Drugs Clinical Trials
The pending Northern District of California lawsuit alleges the company misled investors by filing its aficamten NDA without a REMS after FDA discussions, affecting the expected review timeline.
